Amyotrophic Lateral Sclerosis has a lifetime risk of about 1 in 400, yet once symptoms begin, half of people die within roughly 3 years. At the same time, respiratory measures like FVC decline, biomarker signals such as neurofilament light chain, and care decisions like NIV or PEG can shift what happens next, making the story far more data driven than most people expect.
Key Takeaways
- 1 in 400 people develop ALS during their lifetime, reflecting lifetime risk of amyotrophic lateral sclerosis.
- 50% of people with ALS die within about 3 years of symptom onset, describing a commonly cited survival distribution.
- ~60% of ALS cases begin with limb weakness (limb onset), representing the share of cases with limb-first symptoms.
- In DBS/biomarker research, forced vital capacity (FVC) thresholds (e.g., FVC <80% predicted) are used clinically to indicate meaningful respiratory decline, quantifying respiratory impairment levels.
- ALS therapeutic development increasingly uses biomarkers and functional scales such as ALSFRS-R; ALSFRS-R has a total score of 48, providing a quantifiable outcome measure used in trials.
- ALSFRS-R has 12 items scored 0–4 each, totaling 48 points, quantifying how functional decline is measured.
- Riluzole improved median survival by about 2–3 months versus placebo in pivotal trials, indicating the magnitude of effect for the first approved ALS therapy.
- Sodium phenylbutyrate/taurursodiol (PB/TURSO) did not significantly improve the primary endpoint in the original phase 3 trial (ALS Untangled), indicating lack of efficacy at that primary measure.
- Nusinersen is excluded; for ALS, edaravone’s evidence included subgroup analyses where the benefit was more apparent in patients meeting specific criteria used in the original trial population, quantifying effect context.
- In the NEJM edaravone trial report, the study enrolled 204 participants, quantifying randomized trial evidence base size.
- In a pivotal SOD1 gene-targeting trial report, the tofersen study included 147 participants total across groups, quantifying sample size for regulatory-evidence generation.
- A common phase 1/2 ALS trial enrollment typically targets dozens of participants (e.g., ~50 in many randomized phase 2 studies), quantifying trial size used in development.
- In the U.S., the average cost of a home health aide visit is on the order of tens of dollars per hour (varies by state and payer), affecting downstream ALS care costs.
- The ALS Association’s comprehensive care model includes multidisciplinary clinic care; the standard model uses neurologists, respiratory therapists, speech-language pathologists, dietitians, and social workers, enabling measurable care inputs.
- In the U.S., average monthly out-of-pocket costs for specialty prescription drugs can exceed $300 for many insured patients depending on plan design, quantifying potential patient cost burden relevant to ALS therapies.
Around 1 in 400 people develop ALS, with about half dying within three years of symptom onset.
Related reading
01 · Category
Epidemiology5 stats
01
1 in 400 people develop ALS during their lifetime, reflecting lifetime risk of amyotrophic lateral sclerosis.
02
50% of people with ALS die within about 3 years of symptom onset, describing a commonly cited survival distribution.
03
~60% of ALS cases begin with limb weakness (limb onset), representing the share of cases with limb-first symptoms.
04
In a population-based study, ALS incidence was reported as ~2 per 100,000 person-years, quantifying annual new cases in populations.
05
In a large U.S. cohort, median ALS onset age was 65 years, representing typical age at disease onset.
Interpretation
Epidemiology Interpretation
From an epidemiology standpoint, ALS is uncommon but far from rare, with a 1 in 400 lifetime risk and about 2 new cases per 100,000 person years, and it most often presents in later life with a median onset age of 65 and around half of patients dying within about three years of symptom onset.
02 · Category
Biomarkers & Endpoints10 stats
01
In DBS/biomarker research, forced vital capacity (FVC) thresholds (e.g., FVC <80% predicted) are used clinically to indicate meaningful respiratory decline, quantifying respiratory impairment levels.
02
ALS therapeutic development increasingly uses biomarkers and functional scales such as ALSFRS-R; ALSFRS-R has a total score of 48, providing a quantifiable outcome measure used in trials.
03
ALSFRS-R has 12 items scored 0–4 each, totaling 48 points, quantifying how functional decline is measured.
04
In a major trial platform, the rate of decline in ALSFRS-R per month (slopes) is used as a quantifiable endpoint rather than absolute score, enabling measurable change over time.
05
The King’s staging system for ALS uses stages I–IV (and subdivisions) to quantify disease progression by functional status, providing a measurable staging endpoint.
06
In ALS clinical research, neurophysiology uses compound muscle action potentials (CMAP) amplitudes and nerve conduction measures; studies report quantitative CMAP changes over time, providing measurable biomarker dynamics.
07
In a clinical study, CSF NfL levels were significantly higher in ALS patients than controls, quantifying biomarker separation.
08
Serum/CSF neurofilament light chain (NfL) has been used as a prognostic biomarker with statistically significant associations with survival and progression, quantifying risk stratification.
09
A longitudinal study reported that CSF NfL correlated with ALSFRS-R slope (faster decline at higher NfL), quantifying biomarker-to-function linkage.
10
In a study, baseline plasma NfL levels predicted ALS survival with statistically significant hazard ratios comparing higher versus lower NfL groups, quantifying risk stratification.
Interpretation
Biomarkers & Endpoints Interpretation
Across ALS Biomarkers and Endpoints research, tools like the ALSFRS-R total score of 48 and monthly ALSFRS-R slopes, alongside neurofilament light chain levels that predict survival and track with faster functional decline, are increasingly used to quantify disease progression and risk rather than relying on single-time clinical impressions.
03 · Category
Therapy Effectiveness5 stats
01
Riluzole improved median survival by about 2–3 months versus placebo in pivotal trials, indicating the magnitude of effect for the first approved ALS therapy.
02
Sodium phenylbutyrate/taurursodiol (PB/TURSO) did not significantly improve the primary endpoint in the original phase 3 trial (ALS Untangled), indicating lack of efficacy at that primary measure.
03
Nusinersen is excluded; for ALS, edaravone’s evidence included subgroup analyses where the benefit was more apparent in patients meeting specific criteria used in the original trial population, quantifying effect context.
04
In PEG observational work, patients receiving PEG had median survival of 1–2 years in reported cohorts versus shorter survival in non-PEG groups, quantifying real-world prognostic difference.
05
In observational cohorts, NIV use was associated with median survival extensions on the order of months, quantifying outcome association for respiratory support.
Interpretation
Therapy Effectiveness Interpretation
Within the Therapy Effectiveness category, riluzole shows the most consistent early survival benefit at about 2 to 3 months versus placebo, while other later therapies and supports such as PB/TURSO show no significant primary endpoint gain in the original trial and real-world measures like PEG and NIV are associated with survival improvements ranging from roughly 1 to 2 years and several months respectively.
More related reading
04 · Category
Regulatory & Trials6 stats
01
In the NEJM edaravone trial report, the study enrolled 204 participants, quantifying randomized trial evidence base size.
02
In a pivotal SOD1 gene-targeting trial report, the tofersen study included 147 participants total across groups, quantifying sample size for regulatory-evidence generation.
03
A common phase 1/2 ALS trial enrollment typically targets dozens of participants (e.g., ~50 in many randomized phase 2 studies), quantifying trial size used in development.
04
The clinical trial registry shows multiple ongoing ALS interventional studies with recruitment/active status; as of the FDA and ClinicalTrials.gov listings, trials are actively enrolling, quantifying trial pipeline activity.
05
Orphan Drug Designation is used for ALS; in the FDA’s orphan drug database, several ALS therapies have received orphan designations, quantifying regulatory incentives for rare diseases.
06
ClinicalTrials.gov tracks ALS interventional studies; the registry provides measurable fields including recruitment status and locations, quantifying trial activity.
Interpretation
Regulatory & Trials Interpretation
For the Regulatory & Trials angle, ALS drug development is showing a steady pipeline with pivotal evidence coming from relatively small but decisive cohorts like 204 participants in the NEJM edaravone trial and 147 in the tofersen study, alongside multiple actively enrolling interventional trials in ClinicalTrials.gov.
05 · Category
Health Systems6 stats
01
In the U.S., the average cost of a home health aide visit is on the order of tens of dollars per hour (varies by state and payer), affecting downstream ALS care costs.
02
The ALS Association’s comprehensive care model includes multidisciplinary clinic care; the standard model uses neurologists, respiratory therapists, speech-language pathologists, dietitians, and social workers, enabling measurable care inputs.
03
In the U.S., average monthly out-of-pocket costs for specialty prescription drugs can exceed $300for many insured patients depending on plan design, quantifying potential patient cost burden relevant to ALS therapies.
04
The ALS Association reports that the ALS Center of Excellence program includes hundreds of clinicians and multidisciplinary care teams across multiple states, quantifying program scale.
05
The ALS Association reported over 10,000 people were connected to its services during 2022 (care/support engagement metric), quantifying beneficiary reach.
06
The ALS Association annual report for 2023 shows programmatic engagement and services with measurable counts; e.g., volunteer and community support activity described in the report, quantifying engagement scale.
Interpretation
Health Systems Interpretation
From a health systems perspective, ALS care is increasingly shaped by measurable capacity and cost pressures, with the ALS Association connecting more than 10,000 people to its services in 2022 and sustaining a large multistate network of hundreds of clinicians, while patients also face monthly out-of-pocket drug costs that can exceed $300, underscoring how system-level resources and expenses directly influence access to ALS therapies.
06 · Category
Funding & R&d1 stats
01
In a U.S. analysis of nonprofit spending, The ALS Association reported $56.6 million in program services in FY2023, quantifying nonprofit investment in ALS programs.
Interpretation
Funding & R&d Interpretation
In FY2023, the ALS Association’s $56.6 million in program services shows substantial funding directed into ALS programs under the Funding and R and d category.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Christopher Morgan. (2026, February 13). Amyotrophic Lateral Sclerosis Statistics. Gitnux. https://gitnux.org/amyotrophic-lateral-sclerosis-statistics
MLA
Christopher Morgan. "Amyotrophic Lateral Sclerosis Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/amyotrophic-lateral-sclerosis-statistics.
Chicago
Christopher Morgan. 2026. "Amyotrophic Lateral Sclerosis Statistics." Gitnux. https://gitnux.org/amyotrophic-lateral-sclerosis-statistics.
Sources & references
33 datasets cited across this report · attribution is report-level
+22 additional datasets cited (not shown individually)